公开(公告)号：RS57969B1

公开(公告)日：2019-01-31

申请号：RSP20181387

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME WIREDU ,  O'NEIL SIMON ADAM ,  ZHANG YUEGANG ,  MUDUNURI PRAVEEN ,  VAN ALSTEN JOHN GREGG ,  SONG BIN ,  STAVROPOULOS KATHY ,  STROHMEIER MARK ,  WALDO MICHAEL ,  NAVAMAL METTACHIT ,  KADIYALA IRINA NIKOLAEVNA

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/00

公开(公告)号：NZ620027A

公开(公告)日：2015-05-29

申请号：NZ62002708

申请日：2008-09-15

Applicant: VERTEX PHARMA

Inventor： FENG YUSHI ,  LOOKER ADAM ,  ZHANG YUEGANG ,  DEMATTEI JOHN ,  MUDUNURI PRAVEEN ,  ROEPER STEFANIE ,  HARRISON CRISTIAN

IPC: A61K31/47 ,  A61P3/00 ,  A61P3/10 ,  A61P25/28 ,  A61P27/02 ,  A61P35/00 ,  C07D215/233

Abstract: Disclosed is a compound selected from N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) 2-methylbutyric acid. Also disclosed is a method of making the crystalline forms, pharmaceutical compositions and kits comprising the crystalline forms and the use of the crystalline forms for the manufacture of a medicament for the for treating or lessening the severity of a disease in a patient, wherein said disease is selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, lipid processing deficiencies, lysosomal storage diseases, neurodegenerative diseases, polyglutamine neurological disorders, spongiform encephalopathies, COPD, dry-eye disease, and Sjogren’s disease .

公开(公告)号：CA2927631A1

公开(公告)日：2015-04-23

申请号：CA2927631

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： KADIYALA IRINA NIKOLAEVNA ,  O'NEIL SIMON ADAM ,  STROHMEIER MARK ,  WALDO MICHAEL ,  NAVAMAL METTACHIT ,  STAVROPOULOS KATHY ,  MUDUNURI PRAVEEN ,  SONG BIN ,  VAN ALSTEN JOHN GREGG ,  NTI-ADDAE KWAME WIREDU ,  ZHANG YUEGANG

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.

公开(公告)号：CA2796642A1

公开(公告)日：2011-10-27

申请号：CA2796642

申请日：2011-04-22

Applicant: VERTEX PHARMA

Inventor： VAN GOOR FREDRICK F ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  ALCACIO TIM EDWARD ,  AREKAR SNEHA G ,  JOHNSTON STEVEN C ,  KADIYALA IRINA NIKOLAEVNA ,  KESHAVARZ-SHOKRI ALI ,  KRAWIEC MARIUSZ ,  LEE ELAINE CHUNGMIN ,  MEDEK ALES ,  MUDUNURI PRAVEEN ,  SULLIVAN MARK JEFFREY ,  ZAMAN NOREEN TASNEEM ,  ZHANG BEILI ,  ZHANG YUEGANG ,  ZLOKARNIK GREGOR

IPC: A61K31/4704 ,  A61K31/404 ,  A61K31/443

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

公开(公告)号：MX2010002974A

公开(公告)日：2010-07-29

申请号：MX2010002974

申请日：2008-09-15

Applicant: VERTEX PHARMA

Inventor： DEMATTEI JOHN ,  HARRISON CRISTIAN ,  FENG YUSHI ,  LOOKER ADAM ,  MUDUNURI PRAVEEN ,  ROEPER STEFANIE ,  ZHANG YUEGANG

IPC: A61K31/47 ,  A61P3/00 ,  A61P3/10 ,  A61P25/28 ,  A61P27/02 ,  A61P35/00 ,  C07D215/233

Abstract: Se describen en la presente formas sólidas de N- [2,4-bis (1,1-dimetiletil) -5-hidroxiferxil] -1,4-dihidro-4-oxoquinolin-3-c arboxamida, entre las que se incluyen las formas cristalinas de la misma.

公开(公告)号：HUE051275T2

公开(公告)日：2021-03-01

申请号：HUE18188034

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME ,  O'NEIL SIMON ADAM ,  ZHANG YUEGANG ,  MUDUNURI PRAVEEN ,  VAN ALSTEN JOHN GREGG ,  SONG BIN ,  STAVROPOULOS KATHY ,  STROHMEIER MARK ,  WALDO MICHAEL ,  NAVAMAL METTACHIT ,  KADIYALA IRINA NIKOLAEVNA

IPC: A61P35/00

公开(公告)号：NZ719163A

公开(公告)日：2021-01-29

申请号：NZ71916314

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： KADIYALA IRINA ,  MUDUNURI PRAVEEN ,  WALDO MICHAEL ,  NTI-ADDAE KWAME ,  O’NEIL SIMON ,  ZHANG YUEGANG ,  SONG BIN ,  VAN ALSTEN JOHN GREGG ,  STROHMEIER MARK ,  STAVROPOULOS KATHY ,  NAVAMAL METTACHIT

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/00

Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. The co-crystals of (S)-N-methyl-8-(1-((2’-methyl-[4,5’-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide with adipic acid are DNA-dependent protein kinase (DNA-PK) inhibitors which may be useful for the treatment of cancer.

公开(公告)号：RS60426B1

公开(公告)日：2020-07-31

申请号：RSP20200607

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME WIREDU ,  O'NEIL SIMON ADAM ,  ZHANG YUEGANG ,  MUDUNURI PRAVEEN ,  VAN ALSTEN JOHN GREGG ,  SONG BIN ,  STAVROPOULOS KATHY ,  STROHMEIER MARK ,  WALDO MICHAEL ,  NAVAMAL METTACHIT ,  KADIYALA IRINA NIKOLAEVNA

IPC: C07D401/14 ,  A61K31/506 ,  A61P35/00

公开(公告)号：UA120915C2

公开(公告)日：2020-03-10

申请号：UAA201605244

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME WIREDU ,  O'NEIL SIMON ADAM ,  ZHANG YUEGANG ,  WALDO MICHAEL ,  MUDUNURI PRAVEEN ,  SONG BIN ,  VAN ALSTEN JOHN GREGG ,  STROHMEIER MARK ,  STAVROPOULOS KATHY ,  KADIYALA IRINA NIKOLAEVNA ,  NAVAMAL METTACHIT

Abstract: Данийвинахідстосуєтьсякомпозиційі співкристалів, кожна(ий) зякихвключаєсполукуформули (І), щомаєструктуру: , (I) декожнийз R1 і R2 означаєводеньабодейтерій, іутворювачспівкристалавибираютьізгрупи, щоскладаєтьсяз адипіновоїкислоти, лимонноїкислоти, фумаровоїкислоти, малеїновоїкислоти, бурштиновоїкислотиабобензойноїкислоти. Такожу рамкиданоговинаходувходятьспособиїходержанняі застосування.

公开(公告)号：ES2741444T3

公开(公告)日：2020-02-11

申请号：ES14802787

申请日：2014-11-12

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME ,  WALDO MICHAEL ,  O'NEIL SIMON ,  VAN ALSTEN JOHN ,  MACIKENAS DAINIUS ,  MUDUNURI PRAVEEN ,  SHI YI ,  LEDEBOER MARK ,  JURKAUSKAS VALDAS ,  MEDEK ALES ,  JONES STEVEN ,  BYRN RANDAL ,  ASMAL MOHAMMED ,  ROBERTSON SARAH ,  TSAI WANJUNG

IPC: C07D403/04 ,  A61K31/506 ,  A61P31/16 ,  C07D471/04

Abstract: Una forma polimórfica del compuesto (1), en donde el compuesto (1) está representado por la siguiente fórmula estructural:**Fórmula** y donde la forma polimórfica es una sal cristalina de HCl del semihidrato del compuesto (1), estando dicha forma polimórfica caracterizada además por uno o más picos que corresponden a valores de 2-theta medidos en grados de 10,5 ± 0 10 ,2, 5,2 ± 0,2, 7,4 ± 0,2 y 18,9 ± 0,2 en un patrón de difracción de rayos X en polvo.